Trial Profile
The analysis of Eribulin in patients with unresectable breast cancer, retorospective multicenter study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2016
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 23 Oct 2014 Status changed from not yet recruiting to completed as reported by University Hospital Medical Information Network - Japan
- 28 Jul 2014 New trial record